178 related articles for article (PubMed ID: 21735096)
1. CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.
Perea SE; Baladron I; Garcia Y; Perera Y; Lopez A; Soriano JL; Batista N; Palau A; Hernández I; Farina H; Garcia I; Gonzalez L; Gil J; Rodriguez A; Solares M; Santana A; Cruz M; Lopez M; Valenzuela C; Reyes O; López-Saura PA; González CA; Diaz A; Castellanos L; Sanchez A; Betancourt L; Besada V; González LJ; Garay H; Gómez R; Gómez DE; Alonso DF; Perrin P; Renualt JY; Sigman H; Herrera L; Acevedo B
Mol Cell Biochem; 2011 Oct; 356(1-2):45-50. PubMed ID: 21735096
[TBL] [Abstract][Full Text] [Related]
2. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.
Perera Y; Farina HG; Gil J; Rodriguez A; Benavent F; Castellanos L; Gómez RE; Acevedo BE; Alonso DF; Perea SE
Mol Cancer Ther; 2009 May; 8(5):1189-96. PubMed ID: 19417160
[TBL] [Abstract][Full Text] [Related]
3. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
Perea SE; Reyes O; Baladron I; Perera Y; Farina H; Gil J; Rodriguez A; Bacardi D; Marcelo JL; Cosme K; Cruz M; Valenzuela C; López-Saura PA; Puchades Y; Serrano JM; Mendoza O; Castellanos L; Sanchez A; Betancourt L; Besada V; Silva R; López E; Falcón V; Hernández I; Solares M; Santana A; Díaz A; Ramos T; López C; Ariosa J; González LJ; Garay H; Gómez D; Gómez R; Alonso DF; Sigman H; Herrera L; Acevedo B
Mol Cell Biochem; 2008 Sep; 316(1-2):163-7. PubMed ID: 18575815
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.
Perera Y; Costales HC; Diaz Y; Reyes O; Farina HG; Mendez L; Gómez RE; Acevedo BE; Gomez DE; Alonso DF; Perea SE
J Pept Sci; 2012 Apr; 18(4):215-23. PubMed ID: 22407768
[TBL] [Abstract][Full Text] [Related]
5. Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.
Solares AM; Santana A; Baladrón I; Valenzuela C; González CA; Díaz A; Castillo D; Ramos T; Gómez R; Alonso DF; Herrera L; Sigman H; Perea SE; Acevedo BE; López-Saura P
BMC Cancer; 2009 May; 9():146. PubMed ID: 19439079
[TBL] [Abstract][Full Text] [Related]
6. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
Perea SE; Baladrón I; Valenzuela C; Perera Y
Semin Oncol; 2018 Jan; 45(1-2):58-67. PubMed ID: 30318085
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of the CK2-mediated phosphorylation of B23/NPM in cancer cells selectively modulates genes related to protein synthesis, energetic metabolism, and ribosomal biogenesis.
Perera Y; Pedroso S; Borras-Hidalgo O; Vázquez DM; Miranda J; Villareal A; Falcón V; Cruz LD; Farinas HG; Perea SE
Mol Cell Biochem; 2015 Jun; 404(1-2):103-12. PubMed ID: 25805179
[TBL] [Abstract][Full Text] [Related]
8. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.
Benavent Acero F; Capobianco CS; Garona J; Cirigliano SM; Perera Y; Urtreger AJ; Perea SE; Alonso DF; Farina HG
Lung Cancer; 2017 May; 107():14-21. PubMed ID: 27319334
[TBL] [Abstract][Full Text] [Related]
9. CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome.
Perera Y; Ramos Y; Padrón G; Caballero E; Guirola O; Caligiuri LG; Lorenzo N; Gottardo F; Farina HG; Filhol O; Cochet C; Perea SE
Mol Cell Biochem; 2020 Jul; 470(1-2):63-75. PubMed ID: 32405972
[TBL] [Abstract][Full Text] [Related]
10. Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization.
Gottardo MF; Capobianco CS; Sidabra JE; Garona J; Perera Y; Perea SE; Alonso DF; Farina HG
Sci Rep; 2020 Sep; 10(1):14689. PubMed ID: 32895446
[TBL] [Abstract][Full Text] [Related]
11. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300.
Rosales M; Pérez GV; Ramón AC; Cruz Y; Rodríguez-Ulloa A; Besada V; Ramos Y; Vázquez-Blomquist D; Caballero E; Aguilar D; González LJ; Zettl K; Wiśniewski JR; Yang K; Perera Y; Perea SE
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356831
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.
Perera Y; Toro ND; Gorovaya L; Fernandez-DE-Cossio J; Farina HG; Perea SE
Mol Clin Oncol; 2014 Nov; 2(6):935-944. PubMed ID: 25279177
[TBL] [Abstract][Full Text] [Related]
13. Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support.
Perera Y; Melão A; Ramón AC; Vázquez D; Ribeiro D; Perea SE; Barata JT
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471246
[TBL] [Abstract][Full Text] [Related]
14. CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells.
Ramón AC; Basukala O; Massimi P; Thomas M; Perera Y; Banks L; Perea SE
Viruses; 2022 Jul; 14(8):. PubMed ID: 36016303
[TBL] [Abstract][Full Text] [Related]
15. Protein B23/nucleophosmin/numatrin nuclear dynamics in relation to protein kinase CK2 and apoptotic activity in prostate cells.
Wang G; Pan Y; Ahmad KA; Ahmed K
Biochemistry; 2010 May; 49(18):3842-52. PubMed ID: 20387789
[TBL] [Abstract][Full Text] [Related]
16. Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.
Martins LR; Perera Y; Lúcio P; Silva MG; Perea SE; Barata JT
Oncotarget; 2014 Jan; 5(1):258-63. PubMed ID: 24473900
[TBL] [Abstract][Full Text] [Related]
17. Characterization of low-abundance species in the active pharmaceutical ingredient of CIGB-300: A clinical-grade anticancer synthetic peptide.
Garay H; Espinosa LA; Perera Y; Sánchez A; Diago D; Perea SE; Besada V; Reyes O; González LJ
J Pept Sci; 2018 Jun; 24(6):e3081. PubMed ID: 29676523
[TBL] [Abstract][Full Text] [Related]
18. Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.
Sarduy MR; García I; Coca MA; Perera A; Torres LA; Valenzuela CM; Baladrón I; Solares M; Reyes V; Hernández I; Perera Y; Martínez YM; Molina L; González YM; Ancízar JA; Prats A; González L; Casacó CA; Acevedo BE; López-Saura PA; Alonso DF; Gómez R; Perea-Rodríguez SE;
Br J Cancer; 2015 May; 112(10):1636-43. PubMed ID: 25880012
[TBL] [Abstract][Full Text] [Related]
19. Targeting CK2 mediated signaling to impair/tackle SARS-CoV-2 infection: a computational biology approach.
Miranda J; Bringas R; Fernandez-de-Cossio J; Perera-Negrin Y
Mol Med; 2021 Dec; 27(1):161. PubMed ID: 34930105
[TBL] [Abstract][Full Text] [Related]
20. The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines.
Cirigliano SM; Díaz Bessone MI; Berardi DE; Flumian C; Bal de Kier Joffé ED; Perea SE; Farina HG; Todaro LB; Urtreger AJ
Cancer Cell Int; 2017; 17():42. PubMed ID: 28373828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
